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Background: Genetic polymorphisms in the hepatic cytochrome P450 (CYP2C19) affect the antiplatelet effects of clopidogrel. Rosuvastatin is 
partially metabolized by the same cytochrome. We hypothesized that pharmacokinetic interactions between these drugs might affect their individual 
responses on vascular protection. 
Methods: Patients with stable coronary heart disease (N=20) were submitted to four consecutive 1-wk therapeutic regimens: aspirin, rosuvastatin, 
rosuvastatin plus clopidogrel, or clopidogrel alone. 
Results: Clopidogrel loading dose (300 mg) increased the area under the curve from 0-to the last detectable concentration (AUClast, p<0.001) 
and the maximal concentration (Cmax, p=0.011) of rosuvastatin, but there was modest interaction with clopidogrel 75 mg. Clopidogrel 
concentrations were not affected by rosuvastatin. Rosuvastatin did not reduce the effectiveness of in vitro platelet aggregation inhibition by 
clopidogrel. However, the amount of plasma platelet microparticles increased after withdrawal of rosuvastatin, despite continuous clopidogrel 
therapy. Remarkable improvement in the flow-mediated dilation was observed 24 h after rosuvastatin initiation, and it was not affected by 
concomitant clopidogrel therapy or related to the circulating endothelial progenitor cells. 
Conclusions: This study shows beneficial pharmacokinetic interaction between clopidogrel and rosuvastatin that seems to extend the vascular 
protection provided by each drug, highlighting the importance of the combined therapy for subjects with coronary heart disease.
